• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » Conferences » Conference on Retroviruses and Opportunistic Infections

Conference on Retroviruses and Opportunistic Infections
Conference on Retroviruses and Opportunistic Infections RSS Feed RSS

HIV infected cell

CROI 2022: HIV remission – with transplant, without GVHD – brings hope and insights

Feb. 15, 2022
By Anette Breindl
At the 2022 Conference on Retroviruses and Opportunistic Infections (CROI), investigators reported on a fourth patient who has achieved HIV remission after a stem cell transplant. The patient is the first woman and the first mixed-race person to achieve HIV remission through a transplant procedure. In 2017, she was transplanted with cord blood stem cells lacking a functional CCR5 receptor, which prevents HIV from entering cells.
Read More
COVID-19 research illustration

Studies at CROI show interferons' complex effects, therapeutic potential

Feb. 15, 2022
By Anette Breindl
It's neither a retrovirus nor an opportunistic infection. But of course, SARS-CoV-2 has a prominent place at the table at the 2022 Conference on Retroviruses and Opportunistic Infections (CROI) – starting with the fact that COVID-19 has again forced the conference to go virtual.
Read More

CROI 2021: Sending HIV into the gene desert could be path to functional cure

March 10, 2021
By Anette Breindl
Curing HIV remains a dream for now, but it is clearly not a pipe dream. One of the challenges for developing a vaccine is that there is no natural immune response to model such a vaccine on. Over time, an untreated HIV infection will almost certainly kill its host. However, there is a group of elite controllers – people who, although they cannot eliminate the virus, manage to keep it in check.
Read More
HIV 3D model

At CROI, two-way street between HIV and SARS-CoV-2

March 9, 2021
By Anette Breindl
In 2020, the Conference on Retroviruses and Opportunistic Infections (CROI) was the first medical conference to go virtual, with two days advance warning, when news of infections resulting from a Biogen Inc. conference with about 150 attendees made it abundantly clear that SARS-CoV-2 was circulating, well, probably everywhere.
Read More
Daily pillbox
CROI 2020

For beating HIV, how good is best?

March 12, 2020
By Annette Boyle
Like Berlin patient Timothy Ray Brown before him, London patient Adam Castillejo, whose case was top story of the 2019 Conference on Retroviruses and Opportunistic Infections (CROI), energized the HIV cure research field by his sheer existence. Curing HIV, Pablo Tebas told the audience at a themed discussion on curative strategies, “has been considered [for] a long time the holy grail.”
Read More
HIV antiretroviral drugs
CROI 2020

With Uhambo’s and research lessons, once more unto the breach

March 11, 2020
By Anette Breindl
CYBERSPACE – Continuing improvements in HIV treatment and progress toward a cure notwithstanding, an effective vaccine will be necessary to gain the upper hand in the decades-long fight against the pandemic.
Read More
Budding HIV virions
CROI in the time of COVID-19

Researchers phoning it in at all-virtual 2020 CROI meeting

March 9, 2020
By Anette Breindl
With Friday’s last-minute decision to move to an all-virtual format, the opening session of the 2020 Conference on Retroviruses and Opportunistic Infections (CROI) was certainly an unusual one. “We are in uncharted waters,” conference co-chair Sharon Hillier, Richard Sweet Professor of Reproductive Infectious Disease at the University of Pittsburgh School of Medicine, told the audience via livestream.
Read More
Previous 1 2 3 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 2, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 2, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe